Akero Therapeutics (NASDAQ:AKRO) COO Sells $597,000.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 12,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $47.76, for a total value of $597,000.00. Following the sale, the chief operating officer owned 196,898 shares in the company, valued at approximately $9,403,848.48. This represents a 5.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Thursday, September 11th, Jonathan Young sold 586 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.02, for a total value of $25,209.72.
• On Tuesday, September 2nd, Jonathan Young sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $46.08, for a total value of $576,000.00.
• On Tuesday, August 12th, Jonathan Young sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $47.79, for a total value of $597,375.00.

Akero Therapeutics Trading Down 0.7%

Shares of Akero Therapeutics stock opened at $46.10 on Monday. Akero Therapeutics, Inc. has a 12-month low of $21.34 and a 12-month high of $58.40. The stock has a market cap of $3.69 billion, a P/E ratio of -23.05 and a beta of -0.29. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $47.05 and its 200-day moving average is $46.66.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.11. During the same period in the prior year, the firm posted ($0.81) EPS. Equities research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Trading of Akero Therapeutics

Several large investors have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new stake in shares of Akero Therapeutics during the 1st quarter worth $10,404,000. Ameriprise Financial Inc. bought a new stake in shares of Akero Therapeutics during the 4th quarter worth $422,000. Bank of New York Mellon Corp lifted its position in shares of Akero Therapeutics by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 212,665 shares of the company’s stock worth $8,609,000 after buying an additional 12,235 shares during the last quarter. Allostery Investments LP bought a new stake in shares of Akero Therapeutics during the 1st quarter worth $729,000. Finally, Intech Investment Management LLC lifted its position in shares of Akero Therapeutics by 54.4% during the 1st quarter. Intech Investment Management LLC now owns 58,522 shares of the company’s stock worth $2,369,000 after buying an additional 20,620 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Cowen assumed coverage on Akero Therapeutics in a research note on Monday, August 4th. They issued a “buy” rating on the stock. TD Cowen assumed coverage on Akero Therapeutics in a research note on Monday, August 4th. They issued a “buy” rating and a $76.00 price target on the stock. Wall Street Zen upgraded Akero Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Akero Therapeutics in a research note on Saturday, September 27th. Finally, HC Wainwright assumed coverage on Akero Therapeutics in a research note on Thursday, September 4th. They issued a “buy” rating and a $72.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Akero Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $81.14.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.